Kadmon Holdings, Inc. (KDMN)
Price:
9.50 USD
( - 0 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Myovant Sciences Ltd.
VALUE SCORE:
0
2nd position
Nuvation Bio Inc.
VALUE SCORE:
6
The best
Arcus Biosciences, Inc.
VALUE SCORE:
6
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.
NEWS
Sanofi completes acquisition of Kadmon
globenewswire.com
2021-11-09 09:05:00Sanofi completes acquisition of Kadmon
Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results
accesswire.com
2021-11-04 08:00:00- REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States - - Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million - - Sanofi acquisition of Kadmon expected to close 4Q 2021 - NEW YORK, NY / ACCESSWIRE / November 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2021. "The third quarter was an exceptional period for Kadmon culminating in the availability of REZUROCK to patients living with cGVHD and the significant milestones that were achieved in the months following our strategic commercial launch," said Harlan W.
3 Biotech Stocks That Surged in September
fool.com
2021-10-05 07:39:00Find out why last month was a big one for these three drugmakers.
Kadmon Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting
accesswire.com
2021-10-01 08:01:00NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors, in addition to other IL-15 preclinical work, at the Society for Immunotherapy of Cancer's (SITC 2021) 36th Annual Meeting, taking place virtually November 10 - 14, 2021. Details of the presentations are outlined below.
SHAREHOLDER ALERT: WeissLaw LLP Reminds CXP, JMP, ECHO, and KDMN Shareholders About Its Ongoing Investigations
prnewswire.com
2021-09-30 18:20:00NEW YORK, Sept. 30, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.
3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health
zacks.com
2021-09-30 11:08:25Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.
KADMON HOLDINGS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kadmon Holdings, Inc. - KDMN
prnewswire.com
2021-09-21 19:46:00NEW ORLEANS, Sept. 21, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GTS, HRC, JMP, KDMN, FIBK; Shareholders are Encouraged to Contact the Firm
prnewswire.com
2021-09-20 12:16:00NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Triple-S Management Corporation (NYSE: GTS) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to GuideWell Mutual Holding Corporation for $36.00 per share in cash.
SHAREHOLDER ALERT: WeissLaw LLP Reminds ECHO, KDMN, HRC, and DVCR Shareholders About Its Ongoing Investigations
prnewswire.com
2021-09-17 19:03:00NEW YORK, Sept. 17, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Kadmon Holdings, Inc. - KDMN
prnewswire.com
2021-09-13 15:17:00NEW YORK, Sept. 13, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Kadmon Holdings, Inc. ("KDMN" or the "Company") (KDMN) relating to its proposed acquisition by Sanofi.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kadmon Holdings, Inc.
prnewswire.com
2021-09-09 16:25:00NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kadmon Holdings, Inc. (NASDAQ: KDMN) and its board of directors concerning the proposed acquisition of the company by Sanofi (NASDAQ: SNY).
Kadmon, The Big Short
seekingalpha.com
2021-09-09 01:22:03Kadmon, The Big Short
Kadmon Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Kadmon Holdings, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – KDMN
businesswire.com
2021-09-09 01:20:00NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Kadmon Holdings, Inc. (NASDAQ: KDMN) to Sanofi for $9.50 per share in cash is fair to Kadmon shareholders. Halper Sadeh encourages Kadmon shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Kadmon and its boa
KDMN Stock: Why It Surged Today
pulse2.com
2021-09-08 20:54:13The stock price of Kadmon Holdings Inc (NASDAQ: KDMN) increased 71.13% today. This is why it The post KDMN Stock: Why It Surged Today appeared first on Pulse 2.0.
Shareholder Alert: Ademi LLP investigates whether Kadmon Holdings, Inc. has obtained a Fair Price in its transaction with Sanofi
prnewswire.com
2021-09-08 12:30:00MILWAUKEE, Sept. 8, 2021 /PRNewswire/ -- Ademi LLP is investigating Kadmon (NASDAQ:KDMN), for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi.
Sanofi (SNY) to Buy Kadmon for $1.9B, Add cGVHD Drug Rezurock
zacks.com
2021-09-08 11:00:16Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business.
No data to display
Sanofi completes acquisition of Kadmon
globenewswire.com
2021-11-09 09:05:00Sanofi completes acquisition of Kadmon
Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results
accesswire.com
2021-11-04 08:00:00- REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States - - Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million - - Sanofi acquisition of Kadmon expected to close 4Q 2021 - NEW YORK, NY / ACCESSWIRE / November 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2021. "The third quarter was an exceptional period for Kadmon culminating in the availability of REZUROCK to patients living with cGVHD and the significant milestones that were achieved in the months following our strategic commercial launch," said Harlan W.
3 Biotech Stocks That Surged in September
fool.com
2021-10-05 07:39:00Find out why last month was a big one for these three drugmakers.
Kadmon Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting
accesswire.com
2021-10-01 08:01:00NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors, in addition to other IL-15 preclinical work, at the Society for Immunotherapy of Cancer's (SITC 2021) 36th Annual Meeting, taking place virtually November 10 - 14, 2021. Details of the presentations are outlined below.
SHAREHOLDER ALERT: WeissLaw LLP Reminds CXP, JMP, ECHO, and KDMN Shareholders About Its Ongoing Investigations
prnewswire.com
2021-09-30 18:20:00NEW YORK, Sept. 30, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.
3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health
zacks.com
2021-09-30 11:08:25Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.
KADMON HOLDINGS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kadmon Holdings, Inc. - KDMN
prnewswire.com
2021-09-21 19:46:00NEW ORLEANS, Sept. 21, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GTS, HRC, JMP, KDMN, FIBK; Shareholders are Encouraged to Contact the Firm
prnewswire.com
2021-09-20 12:16:00NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Triple-S Management Corporation (NYSE: GTS) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to GuideWell Mutual Holding Corporation for $36.00 per share in cash.
SHAREHOLDER ALERT: WeissLaw LLP Reminds ECHO, KDMN, HRC, and DVCR Shareholders About Its Ongoing Investigations
prnewswire.com
2021-09-17 19:03:00NEW YORK, Sept. 17, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Kadmon Holdings, Inc. - KDMN
prnewswire.com
2021-09-13 15:17:00NEW YORK, Sept. 13, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Kadmon Holdings, Inc. ("KDMN" or the "Company") (KDMN) relating to its proposed acquisition by Sanofi.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kadmon Holdings, Inc.
prnewswire.com
2021-09-09 16:25:00NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kadmon Holdings, Inc. (NASDAQ: KDMN) and its board of directors concerning the proposed acquisition of the company by Sanofi (NASDAQ: SNY).
Kadmon, The Big Short
seekingalpha.com
2021-09-09 01:22:03Kadmon, The Big Short
Kadmon Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Kadmon Holdings, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – KDMN
businesswire.com
2021-09-09 01:20:00NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Kadmon Holdings, Inc. (NASDAQ: KDMN) to Sanofi for $9.50 per share in cash is fair to Kadmon shareholders. Halper Sadeh encourages Kadmon shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Kadmon and its boa
KDMN Stock: Why It Surged Today
pulse2.com
2021-09-08 20:54:13The stock price of Kadmon Holdings Inc (NASDAQ: KDMN) increased 71.13% today. This is why it The post KDMN Stock: Why It Surged Today appeared first on Pulse 2.0.
Shareholder Alert: Ademi LLP investigates whether Kadmon Holdings, Inc. has obtained a Fair Price in its transaction with Sanofi
prnewswire.com
2021-09-08 12:30:00MILWAUKEE, Sept. 8, 2021 /PRNewswire/ -- Ademi LLP is investigating Kadmon (NASDAQ:KDMN), for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi.
Sanofi (SNY) to Buy Kadmon for $1.9B, Add cGVHD Drug Rezurock
zacks.com
2021-09-08 11:00:16Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business.